HS632 (omalizumab biosimilar)
/ Zhejiang Hisun Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 25, 2020
Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd; N=252 ➔ 60
Enrollment change
August 07, 2020
Comparison of Pharmacokinetics and Safety of Recombinant Anti IgE Humanized Monoclonal Antibody for Injection(HS632) and Omalizumab With a Single Injection (Xolair®)
(clinicaltrials.gov)
- P1; N=252; Not yet recruiting; Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd; Initiation date: Jun 2020 ➔ Oct 2020
Clinical • Trial initiation date
1 to 2
Of
2
Go to page
1